Saglietto Andrea, Ballatore Andrea, Xhakupi Henri, De Ferrari Gaetano Maria, Anselmino Matteo
Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, 10126 Torino, Italy.
J Cardiovasc Dev Dis. 2022 Apr 30;9(5):140. doi: 10.3390/jcdd9050140.
Atrial fibrillation (AF) is independently associated with the onset of cognitive decline/dementia. AF catheter ablation (AFCA) is the most effective treatment strategy in terms of sinus rhythm maintenance, but its effects on dementia prevention remain under investigation. The aim of the present study was to perform a systematic review and meta-analysis of the presently available studies exploring the effect of AFCA on dementia occurrence.
PubMed/MEDLINE databases were screened for articles through 14 March 2022 reporting adjusted time-to-event outcome data comparing AFCA and non-AFCA cohorts in terms of de novo dementia occurrence. A random effect meta-analysis was performed to estimate the meta-analytic hazard ratio (HR) of dementia occurrence in AFCA vs. non-AFCA cohorts, as well as the meta-analytic incidence rate of dementia in the non-AFCA cohort. Based on the aforementioned estimates, the number needed to treat (NNT), projected at median follow-up, was derived.
Four observational studies were included in the analysis, encompassing 40,146 patients (11,312 in the AFCA cohort; 28,834 in the non-AFCA cohort). AFCA conferred a significant protection to the development of dementia with an overall HR of 0.52 (95% CI 0.35-0.76). The incidence rate of dementia in the non-AFCA group was 1.12 events per 100 person-year (95% CI 0.47-2.67). The derived NNT projected to the median follow-up (4.5 years) was 41.
AFCA is associated with a nearly 50% reduction in dementia occurrence during a median 4.5-year follow-up. Future randomized clinical trials are needed to reinforce these findings.
心房颤动(AF)与认知功能下降/痴呆的发生独立相关。房颤导管消融术(AFCA)在维持窦性心律方面是最有效的治疗策略,但其对预防痴呆的效果仍在研究中。本研究的目的是对目前探索AFCA对痴呆发生影响的现有研究进行系统评价和荟萃分析。
在PubMed/MEDLINE数据库中筛选截至2022年3月14日报告调整后的事件发生时间结局数据的文章,这些数据比较了AFCA组和非AFCA组新发痴呆的发生情况。进行随机效应荟萃分析,以估计AFCA组与非AFCA组痴呆发生的荟萃分析风险比(HR),以及非AFCA组痴呆的荟萃分析发病率。根据上述估计值,得出在中位随访期预计的治疗所需人数(NNT)。
分析纳入了四项观察性研究,共40146例患者(AFCA组11312例;非AFCA组28834例)。AFCA对痴呆的发生具有显著的保护作用,总体HR为0.52(95%CI 0.35-0.76)。非AFCA组痴呆的发病率为每100人年1.12例(95%CI 0.47-2.67)。预计中位随访期(4.5年)的NNT为41。
在中位4.5年的随访期内,AFCA与痴呆发生率降低近50%相关。未来需要进行随机临床试验来强化这些发现。